Deals
Pfizer Ends AstraZeneca Deal Amid Chinese Food, Sniping
This article is for subscribers only.
Even in a high-stakes deal worth almost $120 billion, one that would create the world’s biggest drugmaker, the personal details matter.
In a postmortem of the failed takeover talks between Pfizer Inc. and AstraZeneca Plc, a surprise offer, disagreement over a press release and the difference between a personal visit and a telephone chat played a big role. Chinese food had a cameo.